Letters sent to healthcare professionals in July 2017

Letters were sent about ibrutinib, daclizumab, aflibercept, valproate medicines, and arsenic trioxide.

From:
Medicines and Healthcare products Regulatory Agency
Published
15 August 2017
Therapeutic area:
Cancer, Cardiovascular disease and lipidology, Haematology and oncology, Neurology, Ophthalmology and Paediatrics and neonatology

In July 2017, the following letters were sent to relevant healthcare professionals to inform them of updated safety information:

  • Imbruvica鈻�(ibrutinib) and risk of hepatitis B reactivation:
  • Zinbryta鈻� (daclizumab):
  • Aflibercept (Zaltrap鈻�) concentrate for solution for infusion 200 mg/8 mL: some batches contain previous Patient Information Leaflet;
  • Valproate medicines: only for use when no other treatment is effective or tolerated in girls, women of childbearing potential, and women who are pregnant or planning pregnancy; important actions required 鈥� and
  • Shortage of Trisenox (arsenic trioxide, 1 mg/ml concentrate for solution for infusion): 鈥� prescribers should refer responsibilities for off-label or unlicensed use of medicines

Article citation: Drug Safety Update volume 11 issue 1, August 2017: 4.

Updates to this page

Published 15 August 2017